 |
Critical Updates: The Role of Atherosclerosis, Hypertension and Diabetes in Cardiovascular Disease: Call to Action for the Cardiologist CME Robert H. Eckel, MD; George L. Bakris, MD, FAHA, FASN; Alan S. Brown, MD, FACC; Steven M. Haffner, MD; Jack L. Leahy, MD Author Information and Disclosures Release Date: May 9, 2008; Valid for credit through May 9, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME program is based on a symposium of the same name that took place Saturday, March 29, 2008, at McCormick Place in Chicago, IL.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape, VINDICO, or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Vindico Medical Education. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Review established and emerging risk factors for cardiovascular disease;
- Discuss epidemiology and risk factors impacting cardiovascular disease
management;
- Evaluate emerging therapies and clinical data on the treatment of atherosclerosis, hypertension, and diabetes;
- Analyze the interactions of atherosclerosis, diabetes, and obesity in cardiovascular disease.
Author Disclosures Activity
Chair: Robert H. Eckel, MD
Professor of Medicine, Division of Endocrinology, Metabolism, and Diabetes, Division of Cardiology; Professor of Physiology and Biophysics; Professor of Pharmacy; Charles A. Boettcher II Chair in Atherosclerosis; Program Director, Adult General Clinical Research Center, University of Colorado Denver; Director Lipid Clinic, University Hospital, Aurora, Colorado
Disclosure: Speaker:
Takeda. Research Grant Recipient: Sanofi-Aventis. Consultant: Sanofi-Aventis, Merck & Co. Co-Chair: Cardiometabolic Health Congress, Committee on Cardiovascular and Metabolic Diseases (CCMD).
Faculty: George L. Bakris, MD, FAHA, FASN
Professor of Medicine; Director, Hypertensive Diseases Unit, University of Chicago School of Medicine, Chicago,
Illinois
Disclosure: Consultant/Speakers Bureau/Advisory Board: Abbott, Boerhinger-Ingelhelm, BMS/Sanofi-Aventis, Forest, GlaxoSmithKline, Merck, Novartis, Walgreens, Gileada, Sankyo. Grants: NIH (NIDDK/NHLBI), GlaxoSmithKline, Forest.
Alan S. Brown, MD, FACC
Interventional Cardiologist, Midwest Heart Specialists; Director. Midwest Heart Disease Prevention Center. Naperville,
Illinois
Disclosure: Speaker/Speakers Bureau: AstraZeneca, KOS, Pfizer, Reliant, Merck/Schering Plough, Novartis.
Steven M. Haffner, MD
Professor, Internal Medicine, Department of Medicine/Clinical Epidemiology, University of Texas Health Science Center, San Antonio, Texas
Disclosure: Advisory Board: Merck & Co., GlaxoSmithKline. Speakers'
Bureau: Merck & Co., GlaxoSmithKline. Research: GlaxoSmithKline.
Jack L. Leahy, MD
Professor of Medicine; Chief of Division of Endocrinology, Diabetes, and Metabolism, University of Vermont, Burlington, Vermont
Disclosure: Consultant: Merck, Sanofi Aventis. Speaker: Merck, Sanofi Aventis.
External
Reviewer: Michael Miller, MD
Disclosure: Grants: AstraZeneca, Pfizer, Abbott, Merck/Schering Plough. Speaker: AstraZeneca, Pfizer, Abbott, Merck/Schering Plough.
Staff Disclosure
Vindico Medical Education staff has no relevant financial relationship to disclose.
|
 |
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
